Metformin

Overall cancer risk

Change in fasting blood glucose levels

Median Duration (in Months) of Initial Dual Therapy

6-month clinical glycemic control rate

Change in waist circumference at four weeks

Diabetes incidence

Number of Participants With an Adverse Event

Beta cell function

Change in percent mammographic breast density in contralateral (unaffected) breast from baseline to 1 year using two-sample t-test or Wilcoxon rank-sum test

Live birth during the period of ovulation induction

Change in HbA1c from baseline to Week 24.

Blood glucose

Glycosylated hemoglobin (HbA1c)

Ovulation rate

Metabolic late effects

Mean morphometric diffusion capacity for oxygen (MMDC) in placental tissues

Success Rate of Treatment Regimens in Restoring Menstrual Regularity and/or Achieving Pregnancy

Glycated hemoglobin A1c

Change in NT-proBNP levels from baseline to Week 24

Leukocyte telomerase length

Change in hormonal profile and menstural Cycle after Metformin use

Fasting plasma glucose (FPG).

Change in Weight From Baseline at 12 Months or More

Effect of Metformin on first line treatment Refractoriness in high risk failure ALL patients

Duration of menstruation (day)

serum melatonin

evaluate phenotype of T2DM

Cognitive improvement will be assessed using the MATRICS Consensus Cognitive Battery (MCCB) composite score

recruitment rate

Stress hyperglycemia Ratio

the change in glycated hemoglobin (HbA1c) levels

Biochemical parameter:

28 day Mortality.

HVPG response (decrease by ≥ 20 % from baseline or < 12 mmHg).

Extra-cellular volume fraction

incidence of gestational diabetes

Lipid profile

Vaginal and gut microbiota composition before and after intervention recommended and in comparison to women without PCOS.

RANKL and Osteoprotegrin levels in Gingival Crevicular Fluid before & after application of metformin as an adjunctive therapy to non surgical periodontal treatment of Stage III periodontitis.

The comparison of body surface area adjusted cortisol production rate (CPR/BSA) before insulin sensitizing therapy in women with PCOS.

The Number of Participants Who Achieved a Hemoglobin A1C <7%

Weight (wt) in Pounds (Lbs)..

Change in adipose tissue lipolysis in response to exercise

GLP-1 response as incremental area under curve (iAUC)

Health-Related Quality of Life (HRQoL)

Serum testosterone

Time in days to death, non-fatal myocardial infarction, stroke, hospitalization for unstable angina, or symptom-driven coronary revascularization

A neonatal composite adverse outcome of large-for-gestational-age (LGA) birthweight, hypoglycemia, hyperbilirubinemia, and/or death.

Change in BMI Z-score From Baseline to Month 6 in ITT Sample

Change From Baseline in HbA1c at Week 80

Change from baseline in HbA1c at week 48.

Time from study drug initiation (Week 0) to detection of two consecutive HbA1c levels of 7.0% or higher by laboratory tests after Week 16.

Reduction in HbA1c from baseline

Glycosylated Haemoglobin (HbA1c)

Glycated hemoglobin (HbA1c)

Mean Blood Glucose Concentration After First Day of Treatment

A change in liver steatosis will be assessed through fibro CAP score.

HbA1c (%) change at 24 weeks compared to the baseline (Visit 2)

Overall improvement in Fasting Blood Glucose

Combined end-point of non-detectable serum HCV-RNA (<100 copies/mL) and

Proportion of Participants Achieving PASI75 at Week 24

Mean change in Mean Amplitude of Glycemic Excursion (MAGE) from baseline to week 12

Mean Change From Randomization in A1c at Week 26

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 12 Weeks Between Treatment Groups

To investigate whether four months of Metformin treatment before IVF (in-vitro-fertilisation) or ICSI (intra-cytoplasmic sperm injection) will increase clinical pregnancy rate in normal weight PCOS-women

Circulating Endothelial microparticles

Maternal glycemic control 3 months.

Rate of reversal and progression of gastric intestinal metaplasia

Mean Change from Baseline in HbA1c at Week 26

benefit of reducing hypertension in diabetic hypertensive patients

Fibro scan, as well as the changes in FIB4 score and Full lipid profile (total cholesterol, LDL, HDL, VLDL, and triglyceride).

Change in Serum C-reactive Protein (CRP)

HbA1c - difference between final visit and baseline.

Individual's percentage change in body weight

The effect of metformin on blood pressure

Blood Pressure change

MAGE: mean amplitude of glycemic excursion/MODD: mean of daily differences

Change in body weight

Change in total antioxidant capacity (relative and absolute)

Proportion of patients preferring each treatment regimen

Proportion of Women Who Are Eligible, Screened, Enroll and Remain in the Study

liver steatosis index CAP (Controlled Attenuation Parameter) measured by FibroScan

Change in Reactive Hyperemic Index Over the 3-month Treatment Period

HbA1c after the two intervention periods

Cardiovascular risk factors

endothelial progenitor cell

Number of patients with Minimal hepatic encephalopathy

Evaluate lesion size in millimeters

2 hours glucose level after a standardized 75g oral glucose tolerance test (OGTT)

Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire

Metformin-FMD trial: The effect of pretreatment with metformin on FMD of the brachial artery after forearm ischemia and reperfusion.

Change in insulin resistance (HOMA-IR)

organic anionic transporter polypeptide 1B1 (OATP1B1): Clearance over bioavailability (CL/F) of pitavastatin

Feasibility of Randomizing a Cohort of Participants Meeting the Inclusion and Exclusion Criteria of the Study

Change in Insulin Sensitivity From Baseline to Week 12 Post-treatment With Insulin Sensitizing Agent

Metformin AUC

Change of hemoglobin A1c in percentage

Increase in Number of Expressed Genes in Muscle and Adipose Tissue Using RNA Sequencing (RNA-Seq)

Study Endpoints Will Include Measurements of Insulin Sensitivity, Hepatic Insulin Clearance, and Altered Parameters of Lipid Metabolism, Changes in the Histological Features That Define NAFLD, and Quantitative Measurements of Visceral and Peripheral Fat.

Change in PCr Recovery Time

Time to major CV event

Change From Baseline in Hemoglobin A1C (A1C) at Week 24

Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) score

Change from baseline in HbA1c

Change From Baseline in HbA1c From Baseline to Week 24 Provided That it is Prior to Rescue

Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants

Hemoglobin A1c (A1C) Changes From Baseline at Week 24

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Percentage of Participants With at Least One Symptomatic Hypoglycemic Event

Mean change from baseline in HbA1c at Week 24

Treatment Failure (Loss of Glycemic Control)

Change in Glycosylated Hemoglobin (HbA1c) From Baseline to Week 18

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Change from baseline in HbA1c

Change From Baseline in A1C at Week 24

Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c)

Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue

percentage of HbA1c change from baseline

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26.

Change from baseline in glycemic measure HbA1c

Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26

glycated hemoglobin (HbA1c)

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24

Change From Baseline in Hemoglobin A1C at Week 26

Increase in High-Density Lipoprotein cholesterol levels.

Time to progression

Change from Baseline in Fasting Blood Glucose Concentration

To investigate the quality of the metabolic control of diabetes and related variables (daily dose of insulin, body weight).

Change From Baseline in HbA1c (Hemoglobin A1C) at Week24

Change From Baseline in Hemoglobin A1c (A1C) at Week 24 (Phase A, FAS Population)

Change From Baseline in Hemoglobin A1c (A1C) at Week 26

The Mean Increase From Baseline in High-Density Lipoprotein Cholesterol.

Change from baseline in glycated hemoglobin (HbA1c) levels.

The Changes in HbA1c at Week 24

changes in memory Z-score

Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4

Prediabetes or Diabetes

Maximal Walking distance on the 6 minute walk test

Change From Baseline to Endpoint in Weight

HOMA-IR reduction

Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12

Rate of maternal weight gain per week

number of patients with improved nafld and insulin resistance

28 days mortality

Assess the T2DM remission rate in patients with newly diagnosed T2DM treated with either POLYCHEM or with SDC for 16 weeks.

Effect of empagliflozin plus linagliptin vs metformin plus insulin glargine on basal NO activity of renal vasculature (response of RPF (renal plasma flow) to L-NMMA (NG-monomethyl-L-arginine) infusion)

Change From Baseline in Glycosylated Hemoglobin (HbA1c)

Change in A1c From Baseline Through Week 20 Following Rivoglitazone Compared to Pioglitazone as Monotherapy Treatment of Type 2 Diabetes Mellitus

Proper Glycemic Control

Change From Baseline in Glycosylated Hemoglobin A1C (A1C) at Week 24

Change in BMI from baseline

Clinical Outcomes

improvement of body weight, adiposity and inflammation state defined by serum adiponectin, leptin and C reactive protein

Change in Body Mass Index Z-score

Pregnancy Rates

Mean change of motor function measure (MFM) D1 subscore (assessing standing and transfers)

Change From Baseline in Fasting Plasma Glucose (FPG)

Glucose Metabolism

Change from basal fasting and post2h OGTT glucose levels at 6 and 12 months

Hematologic response (erythroid)

HbA1C

Overall survival

HbA1c

Improvement in Left Ventricular Ejection Fraction

Epigenetic aging measurements of "PhenoAge"

Cumulative Ovulation rate confirmed by folliculometry measured by transvaginal ultrasound

Change from baseline in the Expressive Language Sampling (ELS) mean Number of Different Words (NDW) score

Complete resolution of the wart(s) by disappearance of the wart and return of the normal skin markings

Change in defect depth reduction from baseline to 6 months and from baseline to 9 months

Change in Fasting Unscaled Flow Mediated Dilation (FMD) of the Brachial Artery

Change in Bone defect fill

Radiographic bone fill assessed in percentage

Bone defect fill

presence of inflammation

Oral Glucose Tolerance Test

Assessement of Progression Free Survival (PFS) of patients with newly-diagnosed IDH wild-type OXPHOS + GBM (either with or without FGFR3-TACC3 gene fusion) treated with RT plus TMZ combined with metformin

Change of Glycosilated Haemoglobin A1c (HbA1c) From Baseline After 12 Weeks of Treatment

Mean change from baseline in HbA1C after 12 weeks compared to placebo

Mean change from baseline in HbA1c compared to placebo.

Change in Glycated Haemoglobin (HbA1c) [Percentage Point (%-Point)]

The change of HbA1c from baseline to the end of treatment

Absolute change from baseline in HbAlc\n

Clinical response rate

HbA1C

Decrease of at least 5% of body weight and the reduction in the body mass index.

Cumulative CR Rates Within 16 Weeks

triglyceride levels

Differences in the gut microbiome in lean and overweight/obese youth with type 1 diabetes

Disease progression-free survival (PFS)

Change from Baseline in visceral fat area messure in centimers ^2 at 8 weeks

pregnancy rate

Response rate

Adherence for feasibility

Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus

Change From Baseline in 24-hour Weighted Mean Glucose (WMG) at Week 4

Best overall response

- Clinical assessment of disease activity

Change From Baseline in Derived Plasma Glucose Parameter Over a 24-hour Period-fasting and Weighted Mean Glucose Area Under Curve (AUC[0-24 Hour])

Objective response rate of Sintilimab and Metformin(ORR)

- Menstrual Cyclicity ( # menses/ 24 weeks)

Reduction in Melasma Severity Index (MASI) Score

Change in serum uric acid level

Mean Prostate Specific Antigen (PSA) Level

Change in mean early diastolic mitral annular velocity (cm/s)

Median Overall Survival (OS)

Change in HbA1c Levels in Patient Receiving the Various Doses of Leucine and Metformin Combinations

AGE Level Reduction

Measure Metformin Induced effects in phosphorylation of S6K, 4E-BP-1 and AMPK via immunohistochemical analysis

Difference between the two groups in the expression of colonic (NF)-κB proteins.

Beta-cell function

Fasting Serum Glucose

cerebrospinal fluid /plasma leptin ratio

Blood Glucose Measurements

Change in BK channel gene expression

Disease free survival

Response Rate (RR)

Word List Memory Total - ADAS-cog

Proportion of Participants who have completed at least (≥) 80% of planned metformin doses by 6 months

Pathological Complete Response (pCR) rate

Change in pain assessed by the Brief Pain Inventory Interference Scale (BPI) over 6 months

Efficacy of once daily Metformin XR on 24-h blood glucose control

Change in BMI and BMI SDS (calculated using for Disease Control formula - www.cdc.gov.doc) over 6 months of treatment compared to change in BMI and BMI SDS over 6 month 'run-in' period (prior to study start)

Evaluate Feasibility of Patient Randomization, Accrual, and Tissue Collection for Study Conduction

Progression Free Survival

Percent Change in BMI

Effect on Hamilton Depression rating scale score (HAM-D score)

Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint

For phase 1:. Select the recommended dose for SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), in combination with Metformin

The safety and tolerability of metformin in patients with Fragile X Syndrome as assessed by the number of adverse events reported during the course of the study.

Change in modified Melasma Area and Severity Index (mMASI) score from baseline to week 12

Phase I - Dose-Limiting Toxicity

Area Under the Curve (0-t) of Plasma Metformin

Number of patients with adverse events (safety and tolerability)

PK assessment: AUC (Area under plasma concentration-time curve from time zero to infinity)

bioequivalence will be demonstrated if the 90% confidence interval (CI) for the formulation effect is contained within the interval of 0.8000-1.2500 for AUC(0-t), AUCinf and Cmax with respect to both dapagliflozin and metformin.

Regulation of Menstrual Cycle

Incidence of dose limiting toxicity when metformin is added to chemotherapy

AUC0-72 (area under the concentration-time curve of linagliptin in plasma over the time interval from 0 to 72 h)

Number of adverse events

metformin, rosuvastatin Cmax

Determination of maximum tolerated dose (MTD) or administration of the maximum dose provided in the protocol after single and multiple oral administration of IMP.

Plasma Area Under the Curve (AUC(0 to Infinity)) for Metformin

Part A: Maximum Observed Plasma Concentration (Cmax) of Emraclidine and its Metabolite CV-0000364

The plasma concentration of Gemigliptin, Dapagliflozin and Metformin

Pharmacokinetics of metformin: AUC0-inf

Bioequivalence on Cmax, AUC, Tmax,t1/2 parameters

Pharmacokinetic variable - Cmax

Area Under the Concentration-time Curve of Empagliflozin in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Concentration (AUC0-tz)

Area Under the Concentration-time Curve of Linagliptin in Plasma Over the Time Interval 0 to 72 Hours (AUC0-72)

AUClast (Area under the plasma concentration-time curve)

Plasma concentration of canagliflozin following the single dose of drug administration

Bioequivalence

Area Under the Concentration-time Curve of the Analyte in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point (AUC0-tz) (Verapamil + R1 (T1) vs. R1)

Part A: Maximum Observed Plasma Concentration (Cmax) for Bupropion

Renal clearance of Metformin based on genotypes

Module 1: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf) of digoxin, furosemide, metformin and rosuvastatin when dosed alone and in combination with saruparib

Ratio of postprandial maximum concentration (Cmax) of plasma glucose following sucrose load with (Day 1) and without acarbose (Day 0)

Cmax (Maximum Observed Concentration) - Glipizide in Plasma

Pharmacokinetic variable - AUCt

Linagliptin: Maximum Measured Concentration (Cmax)

Bioequivalence

Maximum observed plasma concentration (Cmax) in plasma for metformin with and without BMS-986165

Empa: Area Under the Curve 0 to Infinity (AUC0-∞)

Peak Plasma Concentration Cmax

Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)

Pharmacokinetic (PK) parameters - Cmax

Rate and Extend of Absorption

Part 1: Area Under the Concentration-time Curve of Dabigatran in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞)

Area Under Curve From 0 to tz Hours (AUC0-tz) of Metformin

Incidence of serious adverse events

Cmax: Maximum Observed Plasma Concentration for Metformin Following a Single Dose of Metformin Administered Alone

Cmax

AUC0-t

Structural changes in the human gut microbiota.

Peak Plasma Concentration (Cmax)

AUClast

Compare the pharmacokinetic profiles(Cmax, AUClast) of fixed-dose combination versus free dose combination in healthy volunteers

Plasmatic drug concentration

Area under the metformin plasma concentration-time curve

Saxagliptin Pharmacokinetic (PK) Parameter Area Under the Plasma Concentration Versus Time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf])

Saxagliptin Mean Maximum Observed Plasma Concentration (Cmax)

AUCinf (Area under the plasma concentration-time profile from time zero extrapolated to infinite time) of metformin

Ki-67 proliferation index in T cell

Area under the concentration versus time curve (AUC) of metformin from dosing time (0) to tau (dosing interval) (AUCtau) after 3.5 days.

Area Under the Curve (AUC)

Plasma concentration of LX4211 and metformin after concurrent single-dose administration

Area under the plasma concentration-time curve (AUC) of Andrographis paniculata

Cmax

Maximum Observed Plasma Concentration (Cmax) of Metformin (in absence of PF-06865571)

Pharmacodynamic: Change From Baseline in Mean 24-hour Plasma Glucose (AUC/Duration) at Week 4 (Part 1 - United States)

Maximum Tolerated Dose and/or Recommended Dose within the tested C3 dose range

Metformin: Area under the concentration-time (AUC) curve of the analyte in plasma at steady state over a uniform dosing interval τ (AUCτ,ss)